SCHEMBL6070591

SCHEMBL6070591

Cc1ccc(C(=O)CCC(=O)Nc2ccc3[nH]c4c(ccc5cn[nH]c54)c3c2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTNNB1 P35222 3/20 0.52
WNT3A P56704 3/20 0.52
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
POLB P06746 1/20 0.46
ATM Q13315 1/20 0.45
NPSR1 Q6W5P4 1/20 0.41
TP53 P04637 1/20 0.41
THRB P10828 1/20 0.41
ALDH1A1 P00352 2/20 0.40
MAPT P10636 3/20 0.40
KDM4E B2RXH2 1/20 0.40
P2RY12 Q9H244 1/20 0.40
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
ITK Q08881 2/20 0.39
TERT O14746 1/20 0.39
CNR1 P21554 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6071111 0.82 CNR1 (0.46) MEN1KMT2ANPSR1ALDH1A1KDM4E
SCHEMBL6071196 0.76 KMT2A (0.57) MEN1KMT2APOLBTP53ALDH1A1
SCHEMBL6071391 0.76 ROCK2 (0.46) MEN1KMT2ANPSR1TP53ALDH1A1
SCHEMBL6071488 0.75 MAPK10 (0.59) CTNNB1WNT3AMEN1KMT2APOLB
SCHEMBL6071485 0.74 MAOB (0.56) MEN1KMT2APOLBALDH1A1MAPT
SCHEMBL6070986 0.74 RAB9A (0.46) MEN1KMT2APOLBNPC1
SCHEMBL5583293 0.74 ACHE (0.46) MEN1KMT2AALDH1A1MAPTKDM4E
SCHEMBL6071127 0.73 NPC1 (0.51) POLBTP53ALDH1A1MAPTKDM4E
SCHEMBL6071209 0.72 VCP (0.46) POLBNPC1
SCHEMBL6071038 0.70 MAOB (0.39) ALDH1A1MAPTKDM4ELMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060264493-A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2006-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264493-A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K1, MAP3K19, MAP3K20 CTNNB1 3438/4885WNT3A 2753/4885MEN1 2523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.